Yang David T, Holden Joseph A, Florell Scott R
Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA.
J Cutan Pathol. 2004 Mar;31(3):254-61. doi: 10.1111/j.0303-6987.2003.00175.x.
Distinguishing merkel cell carcinoma (MCC), small cell lung carcinoma (SCLC) metastatic to the skin, and atypical basal cell carcinoma (BCC) can be problematic in some cases. Significant differences in the biology of these tumors necessitate that they need to be distinguished from one another.
We evaluated the immunophenotypic characteristics of 22 MCCs, nine SCLCs, and 19 BCCs using antibodies to cytokeratin 20 (CK20), thyroid transcription factor-1 (TTF-1), CD117, and DNA topoisomerase II-alpha (topo II).
Nineteen of 22 MCCs stained with the antibody to CK20, none stained with anti-TTF-1, and 13 stained with anti-CD117. No SCLC stained with anti-CK20, all stained with anti-TTF-1, and eight stained with anti-CD117. No BCC stained with any of the three markers. The proliferative index (PI), determined by the expression of topo II, was similar for SLCLs (mean 58.5 +/- 9.0%) and MCCs (mean 45.2 +/- 12.4%) and was lowest in BCCs (mean 25.0 +/- 8.7%).
CK20 and TTF-1 appear to be reliable in distinguishing MCC from SCLC. CD117 is expressed in both MCC and SCLC, limiting its diagnostic utility. CK20, TTF-1, and CD117 are not expressed in BCC. The high PI seen in MCCs suggests a role for topoisomerase II inhibitors in their treatment.
在某些情况下,鉴别默克尔细胞癌(MCC)、转移至皮肤的小细胞肺癌(SCLC)和非典型基底细胞癌(BCC)可能存在问题。这些肿瘤在生物学特性上存在显著差异,因此有必要将它们彼此区分开来。
我们使用细胞角蛋白20(CK20)、甲状腺转录因子-1(TTF-1)、CD117和DNA拓扑异构酶II-α(拓扑异构酶II)抗体,评估了22例MCC、9例SCLC和19例BCC的免疫表型特征。
22例MCC中有19例用CK20抗体染色,无一例用抗TTF-1染色,13例用抗CD117染色。没有SCLC用抗CK20染色,所有SCLC都用抗TTF-1染色,8例用抗CD117染色。没有BCC用这三种标志物中的任何一种染色。由拓扑异构酶II的表达确定的增殖指数(PI)在SCLC(平均58.5±9.0%)和MCC(平均45.2±12.4%)中相似,在BCC中最低(平均25.0±8.7%)。
CK20和TTF-1似乎在区分MCC和SCLC方面可靠。CD117在MCC和SCLC中均有表达,限制了其诊断效用。CK20、TTF-1和CD117在BCC中不表达。MCC中所见的高PI提示拓扑异构酶II抑制剂在其治疗中可能起作用。